A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Autor: Víctor Manuel Navas-López, Gemma Pujol-Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas, Javier Martin-de-Carpi

Publikováno v: Anales de Pediatría (English Edition), Vol 88, Iss 2, Pp 89-99 (2018)

Background and objectives: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (I

Externí odkaz: https://doaj.org/article/5328894caf544dce826505f8eb781bb1

Pancreatic Involvement in Pediatric Inflammatory Bowel Disease

Autor: Javier Martín-de-Carpi, Melinda Moriczi, Gemma Pujol-Muncunill, Victor M. Navas-López

Publikováno v: Frontiers in Pediatrics, Vol 5 (2017)

Inflammatory bowel disease (IBD) is a chronic condition that includes two clinical entities: Crohn’s disease and ulcerative colitis. Although both entities mainly affect the gastrointestinal tract are considered multisystemic diseases and may prese

Externí odkaz: https://doaj.org/article/aae7a0106df745ae91c1bdbd1a5c2054

Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study)

Autor: Anat Yerushalmy-Feler, Gemma Pujol-Muncunill, Javier Martin-de-Carpi, Kaija-Leena Kolho, Arie Levine, Christine Olbjørn, Maya Granot, Matteo Bramuzzo, Helena Rolandsdotter, Natalia Mouratidou, Ondrej Hradsky, Luca Scarallo, Manar Matar, Ramit Magen Rimon, Firas Rinawi, Tzippi Shalem, Hisham Najajra, Tim de Meij, Marina Aloi, Marta Velasco Rodríguez-Belvís, Patrizia Alvisi, Anna-Maria Schneider, Patrick van Rheenen, Víctor Manuel Navas-López, Fevronia Kiparissi, Josefa Barrio, Dan Turner, Shlomi Cohen

Publikováno v: Journal of Pediatric Gastroenterology and Nutrition, 75(6), 717-723. Lippincott Williams and Wilkins
Yerushalmy-Feler, A, Pujol-Muncunill, G, Martin-de-Carpi, J, Kolho, K-L, Levine, A, Olbjørn, C, Granot, M, Bramuzzo, M, Rolandsdotter, H, Mouratidou, N, Hradsky, O, Scarallo, L, Matar, M, Rimon, R M, Rinawi, F, Shalem, T, Najajra, H, de Meij, T, Aloi, M, Rodríguez-Belvís, M V, Alvisi, P, Schneider, A-M, van Rheenen, P, Navas-López, V C M, Kiparissi, F, Barrio, J, Turner, D & Cohen, S 2022, ' Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study) : A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN ', Journal of Pediatric Gastroenterology and Nutrition, vol. 75, no. 6, pp. 717-723 . https://doi.org/10.1097/MPG.0000000000003608

OBJECTIVES: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated the effectiveness and safety of dose escalation of UST in pediatric CD. METHODS:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9790dae26a87ed87de98ba1e23fe231b
https://research.rug.nl/en/publications/a0741af3-0a6b-4f24-bc40-ec3617ad0395

41 - BENEFICIO DE LOS PROGRAMAS DE TRANSICIÓN EN ENFERMEDAD INFLAMATORIA INTESTINAL: ESTUDIO BUTTERFLY DE GETECCU Y SEGHNP

Autor: Cristina Rubín de Célix, Javier Martín-de-Carpi, Gemma Pujol-Muncunill, Laura María Palomino, Marta Velasco Rodríguez-Belvís, Rafael Martín-Masot, Víctor Manuel Navas-López, Elena Ricart, María José Casanova, Alejandro Rodríguez Martínez, Eduardo Leo-Carnerero, Alba Alcaraz, Miriam Mañosa, Vicent Hernández, María Consuelo Cobelas Cobelas, César Sánchez, Luis Menchén, Francisco Mesonero, Manuel Barreiro-De Acosta, Nazareth Martínon, Coral Tejido Sandoval, Alicia Rendo Vázquez, Pilar Corsino, Raquel Vicente, Alejandro Hernández-Camba, José Ramón Alberto Alonso, I. Alonso-Abreu, Ana María Castro Millán, Laia Peries Reverter, Beatriz Castro, Estela Fernández-Salgado, M Mercedes Busto Cuiñas, José Manuel Benítez, Lucía Madero, Fernando Clemente, Sabino Riestra, Santiago Jiménez- Treviño, Maia Boscá-Watts, Elena Crehuá-Gaudiza, Marta Calvo Moya, José María Huguet, Ester-María Largo-Blanco, Leticia González Vives, Rocío Plaza, Iván Guerra, Josefa Barrio, Laura Escartín, Erika Alfambra, Noelia Cruz, M Carmen Muñoz, María Guadalupe Muñoz Pino, Manuel Van Domselaar, Belén Botella, David Monfort Miquel, M Carmen Rodríguez Grau, Agustín De La Mano, Yolanda Ber, María Calvo Iñiguez, Teresa de Jesús Martínez-Pérez, María Chaparro, Javier P. Gisbert

Publikováno v: Gastroenterología y Hepatología. 46:S73

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b064b3faf0782baffe3687a9acb65e98
https://doi.org/10.1016/s0210-5705(23)00173-5

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

Autor: Sara Salvador-Martín, Paula Zapata-Cobo, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Cesar Sánchez, Mar Tolín, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Inés Loverdos, Victor Manuel Navas López, Antonio Millán, Lorena Magallares, Ricardo Torres-Peral, Ruth García-Romero, Gemma Pujol-Muncunill, Vicente Merino-Bohorquez, Alejandro Rodríguez, Enrique Salcedo, Beatriz López-Cauce, Ignacio Marín-Jiménez, Luis Menchén, Emilio Laserna-Mendieta, Alfredo J. Lucendo, María Sanjurjo-Sáez, Luis A. López-Fernández

Publikováno v: Scientia
International Journal of Molecular Sciences; Volume 24; Issue 2; Pages: 1797

Adalimumab; Infliximab; Pharmacogenetics Adalimumab; Infliximab; Farmacogenètica Adalimumab; Infliximab; Farmacogenética The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de5f00423cb59a688f998ecdbfe2fca
https://doi.org/10.3390/ijms24021797